The use of mobile telephones does not increase the risk of uveal melanoma, according to a study published online ahead of print by the Journal of the National Cancer Institute.
The use of mobile telephones does not increase the risk of uveal melanoma, according to a study published online ahead of print by the Journal of the National Cancer Institute.
Andreas Stang, MD, MPH of the Martin Luther University of Halle-Wittenberg, Halle, Germany and colleagues conducted a case-control study of uveal melanoma patients (n=459) and control subjects (n=1194) drawn from the general population, melanoma patients’ siblings and ophthalmologists’ offices. The team used a questionnaire to assess any correlation between melanoma and self-assessed mobile phone use (regular, sporadic and never).
The researchers found that, even among regular mobile telephone users, the incidence of uveal melanoma development was similar to that among the control group: odds ratio (OR) = 0.7, 95% confidence interval (CI) = 0.5 to 1.0 versus population control subjects; OR = 1.1, 95% CI = 0.6 to 2.3 versus ophthalmologist control subjects; and OR = 1.2, 95% CI =0.5 to 2.6 versus sibling control subjects.
Thus the researchers concluded that, up to ten years, mobile telephone use is not correlated with an increased risk of uveal melanoma. This conclusion is in contrast to earlier study results showing a relationship between mobile phone exposure and melanoma development.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.